Today, about 2 billion people lack access to necessary medication and therapies. As CEO’s and investors of big pharma companies are prioritizing market access to medicines as part of their Environmental Sustainable Governance (ESG) programs, the Life Sciences team at Capgemini Invent Belgium wanted to gain a deeper insight into the challenges and opportunities faced by the Belgian life science ecosystem in increasing market access. Through a combination of research and interviews with experts in the field, a set of generic solutions – applicable worldwide – have been identified.
Complete the form below and download our whitepaper on the strategic role of Belgium’s life science ecosystem in increasing market access to medicines.
We are sorry, the form submission failed. Please try again.